| Acetylcysteine IV in Acute Immediate Release Paracetamol Overdose
|
SESLHDMG/114 |
|
| Acetylcysteine IV in non-paracetamol induced acute liver injury failure
|
|
|
| Adenosine (antiarrhythmic)
|
SESLHDMG/105 |
|
| Agomelatine in major depression
|
SESLHDPR/646 |
|
| Alteplase to restore CVAD patency
|
SESLHDMG/106 |
|
| Amiodarone Intravenous
|
SESLHDMG/108 |
|
| Andexanet Alfa
|
SESLHDMG/101 |
|
| Argatroban for Heparin Induced Thrombocytopenia (HIT)
|
SESLHDPR/719 |
|
| Aspirin IV in Neurointerventional Procedures and Intensive Care Areas
|
|
|
| Azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis
|
|
|
| Bedaquiline fumarate for resistant pulmonary tuberculosis
|
|
|
| Belatacept for prophylaxis of organ rejection in adult patients receiving/received a kidney transplant
|
SESLHDPR/751 |
|
| Bivalirudin for Heparin induced thrombocytopenia (HIT)
|
SESLHDPR/711 |
|
| Clevidipine
|
SESLHDMG/104 |
|
| Colistimethate (Colistin) IV (Polymyxin E) for Urinary Tract Infections
|
SESLHDPR/608 |
|
| Danaparoid
|
|
|
| Direct Oral Anticoagulants - DOAC Guidelines - CEC
|
|
|
| Fentanyl 2 microg/mL with Adrenaline (epinephrine) 2 microg/mL and Bupivacaine 0.1% epidural infusion
|
|
|
| Ferric Carboxymaltose (Ferinject) - Iron
|
|
|
| Ferric Derisomaltose (Monofer)
|
|
|
| Fomepizole for treatment of toxic alcohol (methanol, ethylene glycol) poisoning
|
|
|
| Fondaparinux for Heparin induced Thrombocytopenia (HIT)
|
|
|
| Fosfomycin Oral Prescribing Protocol
|
SESLHDPR/661 |
|
Heparin - Anticoagulation with Intravenous Heparin Sodium Infusion
|
SESLHDPR/402 |
|
| Idarucizumab in Urgent Dabigatran Reversal
|
SESLHDMG/110 |
|
| Insulin dextrose infusion in Pregnancy RHW
|
SESLHDMG/103 |
|
| Insulin Glargine High Concentration 300 units/mL (Toujeo®)
|
|
|
Iron Infusions
Medicine Guidelines:
|
SESLHDPR/753 |
|
| Iron Polymaltose (Ferrosig)
|
SESLHDMG/112 |
|
| Iron Sucrose (Venofer)
|
|
|
| Lamotrigine for use in Spinal Cord Injury Induced Neuropathic Pain OR for Intractable Trigeminal Neuralgia
|
|
|
| Levosimendan
|
SESLHDMG/113 |
|
| Lidocaine (lignocaine) patch for symptomatic treatment of neuropathic pain refractory or unsuitable for alternative medications
|
SESLHDPR/648 |
|
| Meglumine Diatrizoate and Sodium Diatrizoate (Gastrografin®) in Adult Adhesional Small Bowel Obstruction
|
SESLHDPR/570 |
|
| Methotrexate (oral)
|
SESLHDMG/102 |
|
| Methoxyflurane Inhaler for Acute Pain Management
|
|
|
| Naloxone for treatment of opioid induced over-sedation and respiratory depression
|
|
|
| Naltrexone for treatment of long-acting opioid poisoning
|
SESLHDPR/651 |
|
| Natalizumab
|
|
|
| Olanzapine Pamoate Long-Acting Injection (LAI)
|
|
|
| Pain Management- Ketamine Infusions for Adult Patients with Acute and Chronic Non- Cancer Pain
|
|
|
| Paracetamol
|
SESLHDMG/111 |
|
| Phentolamine in the treatment of dermal necrosis or sloughing following extravasation of peripherally administered noradrenaline (norepinephrine)
|
|
|
| Polymyxin B IV for infections outside of the urinary tract
|
SESLHDPR/573 |
|
| Rituximab
|
|
|
| Sacubitril+Valsartan (Entresto®) for Systolic Heart Failure
|
SESLHDPR/585 |
|
| Sodium Thiosulfate in Calciphylaxis
|
SESLHDPR/659 |
|
| Subcutaneous Furosemide for end stage heart failure with fluid overload in the dying patient
|
|
|
| Subcutaneous Ketamine for Refractory Neuropathic Pain in the Palliative Care Setting
|
|
|
| Subcutaneous levetiracetam for seizure management in palliative care patients
|
|
|
| Subcutaneous levomepromazine for refractory nausea in the palliative care patient and agitation in the terminal phase
|
|
|
| Subcutaneous lidocaine for refractory neuropathic pain in the palliative care setting
|
|
|
| Subcutaneous phenobarbital for refractory terminal agitation and uncontrolled seizure (including status epilepticus) in the imminently dying patient
|
|
|
| Syphilis Management
|
SESLHDMG/107 |
|
| Tirofiban in emergency interventional neuroradiology procedures
|
|
|
| Tolvaptan in inpatient treatment of hyponatraemia
|
SESLHDPR/576 |
|
| Varenicline for smoking cessation
|
SESLHDPR/649 |
|
| Zoledronic Acid for Early/Locally Advanced Breast Cancer
|
|
|
